BACKGROUND: Dialysis grafts fail due to recurrent stenosis and thrombosis. Vasoactive and prothrombotic substances affecting intimal hyperplasia or thrombosis may modify graft outcomes. STUDY DESIGN: Genetic polymorphisms association study of patients enrolled in a multicenter randomized clinical trial. SETTING & PARTICIPANTS: 354 Dialysis Access Consortium (DAC) Study patients receiving a new graft with DNA samples obtained. Participants were randomly assigned to treatment with aspirin plus dipyridamole versus placebo. PREDICTOR: DNA sequence polymorphisms for the following candidate genes and their interaction with the study intervention: methylenetetrahydrofolate reductase (MTHFR), heme oxygenase 1 (HO-1), factor V (F5), transforming growth factor β1 (TGFβ1), klotho, nitric oxide synthase (NOS), and angiotensin-converting enzyme (ACE). OUTCOME: Graft failure (>50% stenosis, angioplasty, thrombosis, surgical intervention, or permanent loss of function). RESULTS: During a median patient follow-up of 34.3 months, 304 grafts failed. After adjusting for clinical factors (patient age, sex, access location, diabetes, cardiovascular disease, baseline aspirin use, body mass index, timing of graft placement, and study treatment) and genetic ancestral background, single-nucleotide polymorphism rs6019 of the factor V gene was associated significantly with graft failure in a dominant model (HR of 1.70 [95% CI, 1.32-2.19; P < 0.001] for G/C and G/G genotypes vs C/C genotypes). There was no significant association between graft failure and polymorphisms of MTHFR, HO-1, TGFβ1, klotho, NOS, or ACE. LIMITATIONS: Small sample size. CONCLUSION: The rs6019 genotype of Factor V is associated with increased risk of graft failure. Anticoagulation may reduce graft failure in patients with the G/C or G/G genotypes.
RCT Entities:
BACKGROUND: Dialysis grafts fail due to recurrent stenosis and thrombosis. Vasoactive and prothrombotic substances affecting intimal hyperplasia or thrombosis may modify graft outcomes. STUDY DESIGN: Genetic polymorphisms association study of patients enrolled in a multicenter randomized clinical trial. SETTING & PARTICIPANTS: 354 Dialysis Access Consortium (DAC) Study patients receiving a new graft with DNA samples obtained. Participants were randomly assigned to treatment with aspirin plus dipyridamole versus placebo. PREDICTOR: DNA sequence polymorphisms for the following candidate genes and their interaction with the study intervention: methylenetetrahydrofolate reductase (MTHFR), heme oxygenase 1 (HO-1), factor V (F5), transforming growth factor β1 (TGFβ1), klotho, nitric oxide synthase (NOS), and angiotensin-converting enzyme (ACE). OUTCOME: Graft failure (>50% stenosis, angioplasty, thrombosis, surgical intervention, or permanent loss of function). RESULTS: During a median patient follow-up of 34.3 months, 304 grafts failed. After adjusting for clinical factors (patient age, sex, access location, diabetes, cardiovascular disease, baseline aspirin use, body mass index, timing of graft placement, and study treatment) and genetic ancestral background, single-nucleotide polymorphism rs6019 of the factor V gene was associated significantly with graft failure in a dominant model (HR of 1.70 [95% CI, 1.32-2.19; P < 0.001] for G/C and G/G genotypes vs C/C genotypes). There was no significant association between graft failure and polymorphisms of MTHFR, HO-1, TGFβ1, klotho, NOS, or ACE. LIMITATIONS: Small sample size. CONCLUSION: The rs6019 genotype of Factor V is associated with increased risk of graft failure. Anticoagulation may reduce graft failure in patients with the G/C or G/G genotypes.
Authors: Hugh C Rayner; Ronald L Pisoni; Brenda W Gillespie; David A Goodkin; Takashi Akiba; Tadao Akizawa; Akira Saito; Eric W Young; Friedrich K Port Journal: Kidney Int Date: 2003-01 Impact factor: 10.612
Authors: P Roy-Chaudhury; B S Kelly; M A Miller; A Reaves; J Armstrong; N Nanayakkara; S C Heffelfinger Journal: Kidney Int Date: 2001-06 Impact factor: 10.612
Authors: Gunnar H Heine; Christof Ulrich; Urban Sester; Martina Sester; Hans Köhler; Matthias Girndt Journal: Kidney Int Date: 2003-09 Impact factor: 10.612
Authors: Bradley S Dixon; Gerald J Beck; Miguel A Vazquez; Arthur Greenberg; James A Delmez; Michael Allon; Laura M Dember; Jonathan Himmelfarb; Jennifer J Gassman; Tom Greene; Milena K Radeva; Ingemar J Davidson; T Alp Ikizler; Gregory L Braden; Andrew Z Fenves; James S Kaufman; James R Cotton; Kevin J Martin; James W McNeil; Asif Rahman; Jeffery H Lawson; James F Whiting; Bo Hu; Catherine M Meyers; John W Kusek; Harold I Feldman Journal: N Engl J Med Date: 2009-05-21 Impact factor: 91.245
Authors: Keattiyoat Wattanakit; Mary Cushman; Catherine Stehman-Breen; Susan R Heckbert; Aaron R Folsom Journal: J Am Soc Nephrol Date: 2007-11-21 Impact factor: 10.121
Authors: Yann C Klimentidis; Jasmin Divers; Krista Casazza; T Mark Beasley; David B Allison; Jose R Fernandez Journal: Hum Genomics Date: 2011-01 Impact factor: 4.639
Authors: Michael Allon; Silvio Litovsky; Carlton J Young; Mark H Deierhoi; Jeremy Goodman; Michael Hanaway; Mark E Lockhart; Michelle L Robbin Journal: Am J Kidney Dis Date: 2013-06-05 Impact factor: 8.860
Authors: Patrizia Natale; Suetonia C Palmer; Valeria M Saglimbene; Marinella Ruospo; Mona Razavian; Jonathan C Craig; Meg J Jardine; Angela C Webster; Giovanni Fm Strippoli Journal: Cochrane Database Syst Rev Date: 2022-02-28
Authors: Gürbey Ocak; Christiane Drechsler; Carla Y Vossen; Hans L Vos; Frits R Rosendaal; Pieter H Reitsma; Michael M Hoffmann; Winfried März; Willem H Ouwehand; Raymond T Krediet; Elisabeth W Boeschoten; Friedo W Dekker; Christoph Wanner; Marion Verduijn Journal: PLoS One Date: 2014-05-09 Impact factor: 3.240
Authors: Tonia C Rothuizen; Gurbey Ocak; Jeffrey J W Verschuren; Friedo W Dekker; Ton J Rabelink; J Wouter Jukema; Joris I Rotmans Journal: PLoS One Date: 2015-11-20 Impact factor: 3.240